• Users Online: 1024
  • Print this page
  • Email this page
CASE REPORT
Year : 2021  |  Volume : 8  |  Issue : 2  |  Page : 73-77

Effect of immune checkpoint inhibitors in gynecologic cancer associated with defective mismatch repair and a rare immunotherapy-related adverse event


Department of Hematology and Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan

Correspondence Address:
Dr. Chien- Ting Liu
Department of Hematology and Oncology, Kaohsiung Chang-Gung Memorial Hospital, No. 123, Ta-Pei Road, Niaosung District, Kaohsiung City 83301
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JCRP.JCRP_4_21

Rights and Permissions

Immune checkpoint inhibitors (ICIs) have improved the outcome and overall survival of patients with cancer. However, predicting the efficacy of immunotherapy remains difficult. The DNA mismatch repair (MMR) system is vital for identifying and repairing mismatched nucleotides during genetic recombination. Cancers with defective MMR involve thousands of mutations and are defined as having microsatellite instability (MSI) and demonstrate a high immunotherapy response rate. Therefore, MSI could be a biomarker for predicting the response to ICIs. Herein, we present two patients with MSI-high gynecologic malignancies who demonstrated a complete response to ICI treatment, but along with panuveitis, a rare immunotherapy-related adverse event in one of the cases.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1080    
    Printed2    
    Emailed0    
    PDF Downloaded93    
    Comments [Add]    

Recommend this journal